Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
230.96(c) 233.23(c) 226.72(c) 227.63(c) 231.68(c) Last
1 233 705 1 077 642 1 390 996 1 040 751 1 113 945 Volume
-2.05% +0.98% -2.79% +0.40% +1.78% Change
More quotes
Financials (USD)
Sales 2019 14 127 M
EBIT 2019 7 412 M
Net income 2019 5 730 M
Finance 2019 38,9 M
Yield 2019 -
Sales 2020 13 888 M
EBIT 2020 7 146 M
Net income 2020 5 420 M
Finance 2020 4 178 M
Yield 2020 -
P/E ratio 2019 7,63x
P/E ratio 2020 7,69x
EV / Sales2019 3,02x
EV / Sales2020 2,78x
Capitalization 42 733 M
More Financials
Company
Biogen is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (84.4%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; -... 
Sector
Pharmaceuticals
Calendar
10/02Presentation
More about the company
Surperformance© ratings of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC.
07/31BIOGEN : Alkermes plc - Diroximel Fumarate Demonstrated Significantly Improved G..
AQ
07/30Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Toler..
GL
07/24Samsung Biologics, Biogen Venture Gets FDA OK for Humira Biosimilar
DJ
07/24BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/23MARKET SNAPSHOT: Stocks Close Higher On Trade Talks Progress, U.S. Debt Ceili..
DJ
07/23Multiple sclerosis drug helps Biogen beat Wall Street profit expectations
RE
07/23GLOBAL MARKETS LIVE : Apple, Continental, Huawei, Facebook…
07/23BIOGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
07/23BIOGEN : SEC Filing 8K
CO
07/23BIOGEN : Half-year results
CO
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Sector news : Biopharmaceuticals
03:20aNOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
02:48aNOVARTIS : CEO Under Fire Over Drug Data
DJ
08/18NOVARTIS : executive sold shares before drug data manipulation made public
RE
08/18NOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
08/16ABBVIE : Gets FDA OK for Rheumatoid Arthritis Drug Rinvoq
DJ
More sector news : Biopharmaceuticals
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 260,08  $
Last Close Price 231,68  $
Spread / Highest target 52,4%
Spread / Average Target 12,3%
Spread / Lowest Target -12,4%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.-23.01%41 986
CSL LIMITED22.81%69 599
ALEXION PHARMACEUTICALS13.86%24 450
GRIFOLS25.41%19 155
SAMSUNG BIOLOGICS CO LTD--.--%15 813
BIOMARIN PHARMACEUTICAL INC.-10.16%12 873